Milestone Pharmaceuticals (MIST) Enterprise Value (2019 - 2026)

Milestone Pharmaceuticals (MIST) has reported Enterprise Value for 8 consecutive years, with -$4.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 107.86% year-over-year to -$4.7 million; the trailing twelve-month figure through Jun 2026 stood at -$4.7 million (down 107.86% YoY), and the FY2025 full-year result was $63.5 million, up 12.96% from the prior year.
• Enterprise Value grew to -$4.7 million in Q2 2026 per MIST's latest filing, from -$156.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at $273.4 million in Q3 2022 and bottomed at -$156.9 million in Q1 2026.
• Historically, Enterprise Value has averaged $28.1 million across 5 years, with a median of $23.3 million in 2023.
• The widest YoY moves for Enterprise Value: up 880.29% in 2024, down 606.11% in 2024.
• Over 5 years, Enterprise Value stood at $71.2 million in 2022, then sank by 91.95% to $5.7 million in 2023, then jumped by 880.29% to $56.2 million in 2024, then gained by 12.96% to $63.5 million in 2025, then slumped by 107.36% to -$4.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$4.7 million, -$156.9 million, and $63.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.